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Age-related white matter changes (WMC) are considered manifestation of arteriolosclerotic small vessel disease and are related to
age and vascular risk factors. Most recent studies have shown that WMC are associated with a host of poor outcomes, including
cognitive impairment, dementia, urinary incontinence, gait disturbances, depression, and increased risk of stroke and death.
Although the clinical relevance of WMC has been extensively studied, to date, only very few clinical trials have evaluated potential
symptomatic or preventive treatments for WMC. In this paper, we reviewed the current understanding in the pathophysiology,
epidemiology, clinical importance, chemical biomarkers, and treatments of age-related WMC.
1.Introduction
Age-related white matter changes (WMC) are prevalent
ﬁndings among the elderly. WMC are considered to be
etiologically related to cerebral small vessel disease and
are important substrates for cognitive impairment and
functional loss in the elderly [1]. Although extensive studies
haveinvestigatedvariousaspectsonWMC,controversiesstill
exist in the pathophysiology and clinical phenotypes, and
consensus regarding to treatments for WMC has not been
reached. In this paper, we aimed to provide an update review
on the epidemiology, pathophysiology, neuroimaging, clini-
cal importance, chemical biomarkers, and treatments of age-
related WMC.
The literature search was conducted using the National
Center for Biotechnology Information (NCBI) PubMed/
Medline to identify relevant articles related to WMC that
were published until June 2011. We used the following
keywords for the search: white matter, white matter changes,
white matter lesions, leukoaraiosis, white matter hyperinten-
sities, and small vessel disease.
The articles were included in this paper if (1) the journal
article was published in English and (2) they were related
to epidemiology, pathophysiology, neuroimaging, genetics,
clinical phenotypes, biomarkers, and treatment of WMC.
Further searches on bibliographies in the main articles and
relevant papers were performed.
2.Prevalence andRiskFactors
WMC are almost endemic in community elderly with
prevalence ranging from 50% to 98% [2–6]. In stroke
patients, prevalence of WMC varies from 67% to 98% [7–
10]. In Alzheimer’s disease, WMC are also common with
prevalence ranges from 28.9% to 100% [11–13]. About 30–
55% of patients with Parkinson’s disease (PD) also harbor
WMC [14–16]. Age [2, 4, 6, 17–20]a n dh y p e r t e n s i o n
[3, 18, 20–30] are established risk factors for WMC. A
recent Manhattan study in community elderly found that
compared with individuals with low blood pressure (BP)
and low ﬂuctuations in BP, the risk of WMC increased with
higher BP and BP ﬂuctuations [31]. Associations of diabetes
mellitus (DM), cholesterol, smoking, and homocysteine are
less consistent between studies. Although past studies had
suggested that WMC are highly heritable [32] and that
several polymorphisms in various candidate genes, such as
apolipoprotein E (epsilon 4±), methylenetetrahydrofolate
reductase (677 cytosine/thymine polymorphism (C/T)), and
angiotensinogen (Met235Thr), were found to be associated
with WMC, [33–35] a recent meta-analyses failed to show2 Journal of Aging Research
convincing evidence for an association between WMC and
the candidate genetic polymorphisms [36].
3. Progression of WMC
Age-related WMC are not static lesions. The lesions may
progress, or even regress, over time. Several longitudinal
studies have investigated the rate and predictors for progres-
sionofWMC[37–47].Perhapsthemostconsistentpredictor
forprogressionofWMCisthebaselineseverityofWMC[44,
47, 48]. Patients with punctate WMC usually have minimal
progressionofWMC,whereasthosewithearlyconﬂuentand
conﬂuent WMC at baseline have rapid progression of WMC
[44,49].IntheAustrianStrokePreventionStudy,themedian
(interquartile range) volume increase over the 6-year period
was 0cm3 in subjects with no lesions, 0.2 (0.0–1.1)cm3 in
subjects with punctuate lesions, 2.7 (0.5–5.9)cm3 in subjects
with early conﬂuent lesions, and 9.3 (7.1–21.0)cm3 for indi-
viduals with conﬂuent WMC at baseline [44]. In AD and PD
patients, the baseline severity of WMC also predicted lesion
progression,ADmedianWMCprogressionwas0.08%,while
PD dementia was 0.07% [50]. Sachdev et al. study in 51
healthy subjects with follow-up duration of 6 years found
that increase in DWMC volume (43.8%) was greater than
that of PVWMC (29.7%) [47]. Furthermore, female may
have more lesion progression than male. A longitudinal
study in 554 elders (313 men, 241 women) aged 70 to 82
years indicated that women had signiﬁcantly higher DWMC
volume than men at baseline; after 3 years followup, they had
accumulated approximately twice as much DWMC as men,
whereas their progression of PVWMC was similar to men
[51].OtherfactorsassociatedwithfasterdeclineinWMCare
higher age, cigarette smoking, and elevated BP [48].
4.Pathology andPhysiology
Pathologically, WMC are characterized by partial loss of
myelin, axons, and oligodendroglial cells; mild reactive
astrocytic gliosis; sparsely distributed macrophages as well
as stenosis resulting from hyaline ﬁbrosis of arterioles and
smaller vessels [52]. Nowadays, the most accepted opinion is
that WMC represents incomplete ischemia mainly related to
cerebral small vessel arteriolosclerosis [53].
Another mechanism is blood-brain barrier dysfunction.
Small vessel alterations could lead to damage of the blood-
brain barrier and chronic leakage of ﬂuid and macro-
molecules in the white matter [53]. Increased concentration
of cerebrospinal ﬂuid albumin and IgG values were found
in patients with CT-detected WMC [54, 55]. A recent MRI
study even found that blood-brain barrier permeability
increased in normal-appearing white matter in patients
with WMC and its presence in normal-appearing white
matter would be consistent with it playing a causal role
in disease pathophysiology [56]. Moreover, a pathological
study showed that albumin extravasation was widespread in
the ageing brain and enhanced in WMC [57]. According
to the location of the lesions, WMC can be divided into
periventricularWMC(PVWMC)anddeepWMC(DWMC).
Pathological studies have shown that PVWMC were related
to disruption of the ependymal lining with subependymal
widening of the extracellular space resulting from disruption
of the blood brain barrier, whereas the DWMC were mainly
related to incomplete ischemic arteriolosclerosis [58, 59].
Vascular risk factors, especially hypertension, cause lipo-
hyalinosis of the media and thickening of the vessel walls,
which attributes to narrowing of the lumen of the small
perforating arteries and arterioles nourishing the deep white
matter [60]. The perforating vessels, which originate from
cortical and leptomeningeal arteries, have a relatively poor
anastomotic system, which makes the white matter vulnera-
ble to cerebral ischemia. Hypertension can also cause distur-
bances in the blood-brain barrier and lead to WMC by cere-
bral edema, activation of astrocytes, or destructive enzymes
or other poisons which pass through the damaged vessel
walls [60]. DM alters the glucose and insulin transfer across
the blood-brain barrier, thus aﬀects regional metabolism
and microcirculation. Chronic hyperglycemia, which further
alters membrane permeability and decreases regional blood
ﬂow, might lead to permanent cell damage. Therefore,
DM seems to be associated with progressive metabolic
disturbance in the cerebrovascular bed that may aﬀect blood
ﬂow and accelerate the white matter ischemia [61, 62].
Recently, postmortem Medical Research Council Cog-
nitive Function and Ageing Study using RNA microarray
and pathway analysis found that 8 major pathways in which
multiple genes showed altered RNA transcription (immune
regulation, cell cycle, apoptosis, proteolysis, ion transport,
cell structure, electron transport, metabolism) and WMC
represented areas with a complex molecular phenotype [63].
Xu et al. study revealed that 241 genes speciﬁc for WMC
expression were associated with inﬂammation, oxidative
stress, detoxiﬁcation, and hormonal responses, included
genes associated with brain repair, long-term potentiation,
and axon guidance, and included genes associated with
oligodendrocyte proliferation, axon repair, long-term poten-
tiation, and neurotransmission [64]. These neurogenetic
ﬁndings support the ischemia, blood-brain barrier dysfunc-
tion, systemic oxidative stress, and inﬂammation in the
pathogenesis of WMC, as well as other potential processes
in the pathogenesis which warrant future research.
Other mechanisms hypothesized to be involved in the
pathophysiology of WMC encompassing dysfunction of
vasomotor reactivity and autoregulation [65–69], chronic
edema [70, 71], apoptosis [72], and endothelial dysfunction
[73, 74].
Therefore, the pathophysiology of WMC is complex and
may be multifactorial. Further studies should address more
on how these diﬀerent pathways interact with each other.
5. NeuroimagingAssessment
WMC are ill deﬁned hypodensities on CT. On MRI, which
is more sensitive than CT on delineating the lesions, they
appear as hypointensities on T1-weighted imaging and
hyperintensities on T2-weighted imaging, proton density
and ﬂuid-attenuated inversion recovery sequences (FLAIR)
(Figure 1). The FLAIR sequence is probably the best to
assess the severity of WMC because of clear distinctionJournal of Aging Research 3
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Figure 1: WMC on CT and MRI. (a) Hypodensities on CT; (b) hypointensities on T1-weighted MRI; (c, d, e) hyperintensities on T2-
weighted MRI, proton-density, and FLAIR sequences, respectively. (d) The lower arrow shows the PVWMC, and the upper one shows the
DWMC.
between ventricles and the PVWMC. Lesions are deﬁned as
PVWMC when their largest diameters are adjacent to the
ventricles, otherwise they are considered as DWMC [75].
The more recent diﬀusion tensor imaging (DTI) technique
provides information on the integrity of white matter tracts
by estimation of the diﬀusion trace (mean diﬀusivity)
and the directionality-fractional anisotropy (FA). In WMC,
mean diﬀusivity is elevated and FA is reduced [76], which
suggests impaired white matter integrity. Measures of DTI
are probably more sensitive than WMC volume in detecting
cognitive changes over time [77].
As to the assessment of WMC severity, various visual
rating scales have been proposed. The visual rating scales
are quick and easy to perform on diﬀerent quality of scans
[78]. However, they varied from each other, and data is not
quantitative and has ceiling eﬀect. In addition, discrepancies
between the various scales may lead to inconsistent ﬁndings.
Two most popular visual rating scales are Fazekas scale [79]
which has been validated histopathologically and Scheltens
scale [80] which is detail with good reliability but relatively
time-consuming. To unite the visual rating for WMC, the
vascular cognitive impairment harmonization standard rec-
ommends the age-related WMC (ARWMC) scale [81] as the
preferred visual rating scale [82]. This scale can be applied to
both MRI and CT with moderate to excellent reliability, and
it has been validated against volumetric measurement and
cognitive impairment [83]. The operationalized ARWMC
scale further gave operational deﬁnitions on ARWMC scale
and improved interrater reliability on CT [84]. Noteworthy
is that visual rating scale for assessing the progression of
WMC is lacking. Both the Rotterdam progression scale [85]
and Schmidt progression scale [42]w e r ec o r r e l a t e dw i t h
volumetric measurements. The Rotterdam progression scale
had moderate to good reliability (weighted Cohen’s =0.63
(intraobserver), 0.59 (interobserver)), whereas the Schmidt
progression scale was less reliable [85, 86].
Nowadays, fully automated techniques and semiauto-
mated segmentation methods become increasingly available.
Diﬀerent from the visual rating scales, volumetric measure-
ment is more accurate and provides continuous data without
ceiling eﬀect. However, it is more time-consuming with
higherrequirementofexpertiseandexcellentqualityofMRI,
which limits its use for research purpose. Overall, volumetric
method is preferred over visual rating scales for longitudinal
studies.
6.ClinicalImportance
6.1. Cognitive Impairment and Decline. Large amounts of
evidence shows that WMC are associated with cognitive4 Journal of Aging Research
impairment (executive function [2, 87, 88], mental pro-
cessing speed [89, 90], and global cognition [2, 91]) and
long-term cognitive decline in both community and stroke
patients [92]. Although some inconsistent results exist, part
of the discrepancies stem from diﬀerent sensitivities of rating
scales for WMC, small sample size, and use of diﬀerent
neuropsychological tests [60]. Longitudinal studies have
demonstrated that WMC progression parallels cognitive
decline [92]. Baseline PVWMC volume was longitudinally
associated with reduced mental processing speed [93]a n d
increased the risk of dementia [94, 95]. In some studies,
when brain atrophy was added into the predicting models,
inﬂuence of WMC became insigniﬁcant whereas global
and/or regional atrophy (i.e., medial temporal lobe atrophy,
cortical gray matter (cGM) and hippocampus atrophy)
exerted greater inﬂuence upon cognitive decline [96–98].
These studies also showed that whole brain or cGM atrophy
was related to severity of WMC. It was thus proposed
that cognitive decline in patients with WMC was mediated
by brain atrophy [96]. The hypothesized mechanisms of
how WMC induce cortical atrophy include demyelination
of axons leading to cortical-subcortical deaﬀerentation and
subsequent secondary cortical neuronal loss, [99, 100]
hypoperfusion, and hypometabolism [101, 102], as well as
concomitant cortical microinfarct, which its detection is
beyondtheabilityofcurrentneuroimagingtechniques[102].
A recent study also showed that severe WMC were associated
with hippocampus atrophy [103]. Moreover, Smith et al.
study in community residents revealed that WMC progres-
sion might predict normal to mild cognitive impairment,
whereas global atrophy predicted mild cognitive impairment
to dementia [104]. With the development of DTI technique,
studies indicated that microstructural integrity of both
WMC and normal-appearing white matter was associated
with cognitive function, regardless of white matter atrophy,
WMC volume, and lacunar infarcts [105, 106].
Certain factors need to be considered in the evaluation
of the relationship between WMC and cognitive impair-
ment. First, the relationship between WMC and cognitive
impairment may not be linear, and a threshold eﬀect was
proposed [107]. Second, cognitive impact of WMC may vary
with its location. PVWMC may aﬀect cognition more than
DWMC. Thus, studies evaluating total WMC may dilute the
cognitive inﬂuence of region-speciﬁc WMC [108]. Third,
psychometric tests in studies may not be comprehensive
for the assessment of executive function; hence, the impact
of WMC may be underestimated [108]. Forth, silent brain
infarcts and microbleeds were reported to be associated with
c o g n i t i v ei m p a i r m e n ta sw e l l[ 109–113], and brain atrophy
(cGM,hippocampusandmedialtemporallobeatrophy)may
be a confounder between WMC and cognitive impairment,
these neuroimaging measures were not assessed in some
studies. Last, future studies should utilize DTI in exploring
the mechanisms of cognitive decline and as a surrogate
marker for disease progression in therapeutic trials.
6.2. Gait Disturbance and PD. Both cross-sectional and
longitudinal studies have found that WMC were associated
with gait disturbance and falls [114–121]. Tasmanian Study
of Cognition and Gait study showed that the risk of
incident falls was doubled in people with WMC volumes
in the highest quintile of its distribution compared with
the lowest (adjusted relative risk 2.32, 95% conﬁdence
interval: 1.28–4.14) [122]. Regardings the WMC location on
gait, Tasmanian Study of Cognition and Gait study found
that bilateral frontal and periventricular WMC-aﬀected
voxels corresponded to major anterior projection ﬁbers
(thalamic radiations, corticofugal motor tracts) and adjacent
association ﬁbers (corpus callosum, superior frontooccipital
fasciculus, short association ﬁbers) showed the greatest
covariance with poorer gait [123]. A DTI study also found
white matter integrity in the genu of corpus callosum
was an important marker of gait in the elderly [124].
Another two recent DTI studies revealed that in elderly
subjects with small vessel disease, widespread disruption
of white matter integrity, predominantly in the normal-
appearing white matter, was involved in gait disturbances
[125, 126]. Iseki et al. study using single-photon emission-
computed tomography suggested that abnormalities in the
basal ganglia-thalamocortical loops partly explained gait
disturbance in WMC [127]. Thus, accumulating evidence
suggests that the disruptions in motor network may account
for gait disturbance in WMC.
WMC correlate with gait disturbance in community
residents, and some of these abnormalities overlap with
features of PD. In postmortem study with 700 parkinsonism
cases, 27 brains (3.9%) showed WMC and/or lacunes in
the basal ganglia, white matter, or brainstem, without
signiﬁcantnigrallesions[128].StudiesalsofoundthatWMC
contributed to dementia in PD patients [16, 129, 130]. Albeit
inconclusive,evidencesaccumulatingthatcognitiveeﬀectsof
WMC tend to preferentially aﬀect executive functions and
may reﬂect frontal lobe WMC [129].
6.3. Urinary Incontinence. Studies had shown that WMC
were associated with urgency urinary incontinence [131–
135]. A community study found that among 100 residents,
64% of them had urinary incontinence. The presence of
WMC in right inferior frontal regions and selected WM
tracts predicted incontinence, incontinence severity, and
degree of bother. The study conﬁrmed a critical role for the
cingulumin bladdercontrolandsuggestedpotential involve-
ment of anterior corona radiata and superior frontooccipital
fasciculus [132]. A study in old women indicated that the
presence of WMC in speciﬁc pathways (anterior thalamic
radiation and superior longitudinal fasciculus) might aﬀect
continence control [136].
6.4. Depression. Lines of evidence suggested that WMC
are associated with late life depression [45, 137–144]. In
poststroke patients, severe deep WMC predicted poststroke
depression [145]. And concurrent atrophy of left inferior
frontal gyrus was associated with depressive symptoms
in poststroke patients with severe WMC [146]. Vascular
depression hypothesis proposed that WMC causes depres-
sion by disrupting ﬁber tracts within frontostriatal circuits
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mood, disruption of frontostriatal circuits might lead to a
disconnection syndrome that corresponded to the clinical
and neuropsychological proﬁle of depression [142]. A DTI
study also found that frontolimbic neural pathways might
contribute to the pathophysiology of depression [147].
6.5. Stroke and Death. The WMC increased the risk for
stroke [8, 95, 148, 149]a n dd e a t h[ 149–151]. A recent meta-
analysis revealed that stroke yielded a signiﬁcant association
of WMC with incident stroke (HR 3.5 (2.5–4.9), P<0.001)
and increased risk of death (HR 2.0 (1.6–2.7), P<0.001)
[92]. In patients treated with thrombolysis for acute stroke,
the rate of symptomatic intracerebral hemorrhage increased
by 10% in patients with severe WMC and multiple lacunes
[152]. WMC were found to be independent determinants for
intracerebral hemorrhage after controlling for age and other
risk factors [152, 153].
WMC were not benign but predict poor clinical and
functional outcomes. Some studies also indicated that they,
especially DWMC, were associated with migraine [154, 155].
And brain stem WMC were associated with dizziness [156].
More studies are in need to explore the clinical signiﬁcance
of WMC.
7. Chemical Biomarkers
Homocysteine is a dietary sulphur-containing amino acid
derivedasanintermediateduringthemetabolismofmethio-
nine [157]. Nutritional deﬁciencies in the vitamin cofactors
(folate, vitamin B12,a n dv i t a m i nB 6) required for homo-
cysteine metabolism may promote hyperhomocyst(e)inemia
[158]. Perini et al. study found that the hyperhomocys-
teinemia in acute stoke stage was associated with higher
risk of small artery disease subtype of stroke [159]. Many
studies had indicated that hyperhomocysteinemia was an
independent predictor for WMC independent of smoking,
hypertension, or age [160–172].
Inﬂammatory biomarkers as intercellular adhesion
molecule-1 (ICAM-1) [173, 174], and high sensitive C-
reactive protein (Hs CRP) [175–177] were also reported
to be associated with WMC load. However, these studies
were cross-sectional so that causal relationship cannot be
determined. Longitudinal studies are needed to study the
relationship between progression of inﬂammatory factors
with progression of WMC.
8. Treatment of WMC
The WMC are predictors for poor clinical outcomes and
important substrates for vascular dementia. The European
Task Force on age-related WMC recommended that clinical
trialsoncerebralsmallvesseldiseaseshouldtargetthosewith
severe WMC and use its progression as surrogate marker
in clinical trials [49]. Albeit WMC are clinically important,
very few clinical studies had been conducted so far to
evaluate treatments for WMC. In this part, studies on treat-
ments for WMC- and WMC- related vascular dementia are
reviewed.
8.1. BP Lowing Therapy. The Epidemiology of Vascular
Ageing MRI study has shown a positive linear relationship
between BP and severity of WMC [28]. Dufouil et al. study
retrospectively found subjects receiving regular treatment of
hypertension had less severe PVWMC than those receiving
no or irregular treatment of hypertension. Due to its
cross-sectional design, the treatment eﬀect of hypertension
on WMC progression cannot be examined in this study.
The Perindopril Protection against Recurrent Stroke Study
(PROGRESS) MRI substudy [178] was a longitudinal ran-
domized placebo-controlled trail investigating the BP lowing
therapy using perindopril or perindopril plus indapamide
on WMC progression. 192 participants were followed up
for 36 months, the mean total volume of new WMC was
signiﬁcantly lower in the active treatment group compared
with the placebo group, and the diﬀerence was greatest for
patients with severe WMC at entry [178].
An open-label study [179] and a post hoc analysis of
a randomized trial [180] showed some beneﬁcial eﬀects of
nimodipine in patients with subcortical vascular dementia.
A recent randomized placebo-controlled trial also found
that the calcium antagonist nimodipine could slow down
global cognitive decline in patients with small vessel disease
related vascular dementia [181]. A recent review in vascular
cognitive impairment indicated that nicardipine has been
investigated in more than 6000 patients, with improvement
of cognitive deterioration in more than 60% of patients
treated [182]. The antihypertensive activity of nicardipine
anditssafetyandeﬀectivenessincognitivedomainsuggested
reconsidering this drug in the treatment of cognitive impair-
ment of vascularorigin and for reducing the risk of recurrent
strokeinpatientsathighriskofit[182].Furtherrandomized
double-blind placebo-controlled trail is needed to explore
the eﬃcacy and safety of nimodipine and nicardipine upon
WMC progression.
Although most studies paid attention to lower BP in
hypertension, noted that low BP was a risk factor for WMC
as well [60]. Another study found that nocturnal BP dipping
was associated with WMC [183]. Thus, a randomized
controlled study dedicated to examine the eﬀects of BP
lowering therapy upon progression of WMC is needed.
8.2. Statins. Statins have long been demonstrated to reduce
cardiovascular events and ischemic stroke among patients
with coronary heart disease [184]. Whether statins aﬀect
progression of WMC is still controversial. The PROSPER
(Prospective Study of Pravastatin in Elderly at Risk) study
examined the eﬀect of pravastatin 40mg daily on the
progressionofWMCin270placebo-treatedsubjectsand265
activesubjectswithinaperiodof33months.Thestudyfailed
to demonstrate an overall beneﬁcial eﬀect of statins upon
WMCprogression.However,dataonproportions ofsubjects
having diﬀerent WMC severity are lacking, and stratiﬁed
analysis based on WMC severity was not performed in the
study. In the Cardiovascular Health Study, 3334 community
participants were followedup over an average observational
period of 7 years [185]. Patients treated with statins were
observedtohaveslightlylesscognitivedeclinethanuntreated
subjects. This signiﬁcant cognitive beneﬁt was associated6 Journal of Aging Research
with reduced progression in cerebral infarcts among the
treated subjects, whereas progression of WMC was not
statistically diﬀerent between these two groups. Although
the ﬁndings may suggest that statins exert cognitive beneﬁts
independent of WMC progression, the visual rating scale
used in that study was unlikely to be sensitive in detecting
WMCprogression [38]. The ROCAS (Regressionof Cerebral
Artery Stenosis) study evaluated simvastatin on WMC
progression in patients with asymptomatic middle cerebral
arterystenosis[38].Twohundredandeightrandomizedsub-
jectswereassignedtoeitherplacebo(n = 102)orsimvastatin
20mg daily (n = 106) for 2 years. Simvastatin group did not
slow the progression of WMC volume compared with the
placebogroup,butinthosewithsevereWMCatbaseline,the
median volume increase in the simvastatin group (1.9cm3)
was less compared with that in the placebo group (3.0cm3;
P = 0.047). However, in this study, treatment probably
preventedWMCprogressionamongthosewithsevereWMC
at baseline was based only on subgroup analysis upon a small
subset of subjects. Furthermore, the subjects of this study
belonged to a high-risk group in that all our subjects had
concurrent MCA stenosis. Hence, the ﬁndings may not be
applicable to patients with less vascular burden or to those
with WMC but without concurrent MCA stenosis.
Furthermore, a recent cross-sectional study showed that
low cholesterol had more severe WMC in acute stroke
patients [10]. Other studies found that low cholesterol
was associated with intracerebral hemorrhage and high
mortality in these patients [186, 187]. Hence, eﬀects of
stains and cholesterol control upon WMC progression are
still uncertain, and randomized clinical trials are needed to
address this issue.
8.3. Acetylcholinesterase Inhibitors and N-Methysl-D-Aspar-
tate (NMDA) Receptor Antagonists. Acetylcholinesterase in-
hibitors (donepezil, galantamine, and rivastigmine) and N-
methyl-D-aspartate (NMDA) receptor antagonists (meman-
tine) have been approved for treatment of AD. Kavirajan
and Schneider reviewed three donepezil, two galantamine,
one rivastigmine, and two memantine placebo-controlled,
randomized, double blinded trials, it showed that cogni-
tive eﬀects on the AD assessment scale-cognitive subscale
(ADAS-cog) were signiﬁcant for all drugs, and post hoc
analyses of donepezil tails suggested greater improvement
in patients with cortical and territorial lesions compared
with those with predominantly subcortical small vessel
disease related lesions [188]. By contrast, cognitive beneﬁts
in the memantine trials appeared to be more pronounced
for patients with small vessel disease than for those with
large vessel disease and such beneﬁts derived largely from
worsening in patients in the placebo-treated groups who
predominantly had small vessel disease [188, 189]. With
regards to safety proﬁle, use of cholinesterase inhibitor
signiﬁcantly increased the odds of having adverse events
(e.g., anorexia, nausea, vomiting, and diarrhea), while
memantine was found to be well tolerable and safe. Overall,
the data is insuﬃcient to support the widespread use
of acetylcholinesterase inhibitors (donepezil, galantamine,
and rivastigmine) and memantine in patients with vas-
cular dementia [188]. Yet, given the potential beneﬁt of
memantine upon subcortical vascular dementia based on
post hoc analysis and its favorable safety proﬁle, conducting
a randomized study evaluating its eﬃcacy in subcortical
vascular dementia may be worthwhile.
Cerebral autosomal dominant arteriopathy with sub-
cortical infarcts and leucoencephalopathy (CADASIL) is a
genetic form of subcortical vascular dementia. A recent
multicentre, 18-week, placebo-controlled, double-blind,
randomized parallel-group trial using donepezil in 168
CADASIL patients revealed that donepezil had no eﬀect on
the vascular ADAS-cog score in CADASIL patients with cog-
nitiveimpairment.Improvementswerenotedonlyonseveral
measuresofexecutivefunction,whichmightpossiblysuggest
that cholinergic pathways were involved in the executive
function [190]. Overall, ﬁndings of this study are similar to
that of previous studies using acetylcholinesterase inhibitors
inthatacetylcholinesteraseinhibitorsmightonlyinducesub-
tlecognitive beneﬁtsamongpatients withvasculardementia.
Another more recent randomized, international, multi-
center, 24-week trial in 974 probable or possible vascular
dementia patients who received donepezil 5mg/d or placebo
found that donepezil improved the vascular ADAS-cog score
but not global function [191]. However, subgroup analysis
on the eﬀects of donepezil upon subcortical type of vascular
dementia was not performed in this study.
8.4. Homocysteine Lowering Therapy. Lines of evidence have
shown that hyperhomocysteinemia was associated with
WMC through endothelial dysfunction [160–172]. Whether
homocysteine lowering therapy by means of multivitamins
retards the progression of WMC or not is uncertain. A
randomized double-blind, parallel, placebo-controlled trial
on homocysteine lowering therapy is the VITAmins TO
Prevent Stroke (VITATOPS) study. 8164 patients with recent
stroke or transient ischaemic attack (within the past 7
months) received one tablet daily of placebo (n = 4089)
or B vitamins (2mg folic acid, 25mg vitamin B6,a n d
0.5mg vitamin B12, n = 4075) with a median followed-
up duration of 3.4 years. Although vitamin treatment was
not signiﬁcantly more eﬀective than placebo in reducing
the incidence of the composite primary endpoint of stroke,
myocardial infarction, or vascular death, in the subgroup
analyses, homocysteine lowering might have preferential
beneﬁt in small vessel disease patients (risk ratio 0.80 (95%
CI:0.67–0.96)) [192]. The VITATOPS MRI substudy is
currently underway to evaluate whether vitamins can slow
WMC progression and/or cognitive decline.
9. Conclusion
WMC are common in elderly, and they are not benign. More
extensive WMC are associated with a host of poor clinical
outcomes.AlthoughWMChavebeenshowntobeassociated
with small vessel disease, age, and other vascular risk factors,
the exact mechanisms explaining such association are still
uncertain. To date, dataon the eﬀectiveness of variousJournal of Aging Research 7
treatments (e.g., BP lowering, statins) in preventing WMC
progression were derived mainly from subgroup analyses.
Randomized studies dedicated in evaluating treatments for
preventing WMC progression and its clinical correlates are
thus urgently needed. Although some studies have suggested
the eﬃcacy of nimodipine, nicardipine, and memantine
in subcortical vascular dementia, further randomized
controlled studies are needed to clarify their eﬀectiveness
and safety.
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